# ABVC BioPharma Highlighted by U.S. Financial Media as One of the Best Biotech Investments; Q3 Licensing Revenue Reaches $1.27 Million, With Clear Clinical Progress Across CNS and Oncology

SILICON VALLEY, CA - October 17, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) (“ABVC” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies in oncology, ophthalmology, and central nervous system (CNS) disorders was recently highlighted by Insider Monkey[1] as one of the “Best Biotech Penny Stocks,” to invest in now, recognizing the company’s financial growth and advancing pipeline.

 Financial Highlights

 * Q2 2025 assets grew 103% year-over-year to $16.2 million; shareholder equity rose 18.7%.
* Q3 2025 licensing revenue totaled $1,275,950, contributed by AiBtl BioPharma, ForSeeCon Eye Corporation, and OncoX BioPharma.

 Pipeline Progress

 * Central Nervous System (CNS)  PDC-1421 (ABV-1504 MDD / ABV-1505 ADHD): Derived from Radix Polygala, a botanical source compound targeting psychiatric disorders with fewer side effects. Currently, Phase IIb CSR has been submitted to FDA. ABV-1504 (MDD): A potential safer alternative to Prozac for the treatment of Major Depressive Disorder; completed Phase II and preparing for global Phase III.
* Oncology  BLI-1401: Metastatic pancreatic cancer, Phase II ongoing. BLI-1301: Myelodysplastic syndromes, Phase II ongoing.

 “We acknowledge that ABVC is currently categorized as a penny stock, but we believe this is simply a stage in our growth journey,” said Dr. Uttam Patil, ABVC's Chief Executive Officer. “Recognition by a financial media outlet, solid Q3 licensing revenue, and well-defined pipeline progress is helping to lay the foundation for potential long-term revaluation.”

 About ABVC BioPharma & Its Industry

 ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct pivotal clinical trials (Phase III) through global partnerships.

 Forward-Looking Statements

 This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

 This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

 Contact:Uttam PatilEmail: uttam@ambrivis.com

[1] Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey

 View the original release on www.newmediawire.com 

---

[Original/Source Press Release](https://www.newmediawire.com/news/abvc-biopharma-highlighted-by-u-s-financial-media-as-one-of-the-best-biotech-investments-q3-licensing-revenue-reaches-1-27-million-with-clear-clinical-progress-across-cns-and-oncology-7083440)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/abvc-biopharma-named-top-biotech-penny-stock-amid-financial-growth/9e2db886c4eee8679f065f8dc26e4dd7) 

 

 



![Blockchain Registration](https://cdn.newsramp.app/newmediawire/qrcode/2510/17/pendL_Vk.webp)